Atea Pharmaceuticals (AVIR) Equity Average (2020 - 2022)
Historic Equity Average for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $661.8 million.
- Atea Pharmaceuticals' Equity Average rose 1223.86% to $661.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $661.8 million, marking a year-over-year increase of 1223.86%. This contributed to the annual value of $628.9 million for FY2021, which is N/A changed from last year.
- Per Atea Pharmaceuticals' latest filing, its Equity Average stood at $661.8 million for Q3 2022, which was up 1223.86% from $670.2 million recorded in Q2 2022.
- Atea Pharmaceuticals' 5-year Equity Average high stood at $695.0 million for Q1 2022, and its period low was -$69.8 million during Q3 2020.
- In the last 3 years, Atea Pharmaceuticals' Equity Average had a median value of $590.9 million in 2021 and averaged $452.9 million.
- Per our database at Business Quant, Atea Pharmaceuticals' Equity Average skyrocketed by 111643.73% in 2021 and then skyrocketed by 1223.86% in 2022.
- Atea Pharmaceuticals' Equity Average (Quarter) stood at $235.6 million in 2020, then soared by 174.04% to $645.8 million in 2021, then increased by 2.49% to $661.8 million in 2022.
- Its Equity Average stands at $661.8 million for Q3 2022, versus $670.2 million for Q2 2022 and $695.0 million for Q1 2022.